

U.S.S.N. 10/632,878

Filed: August 1, 2003

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Remarks

Response to Restriction Requirement


In the Office Action mailed May 3, 2005, the claims were divided into two groups, Group I, claims 1-36, drawn to a method for transporting compounds across a membrane/lipid bilayer, and Group II, claim 37, drawn to a composition for transporting a compound across a membrane/lipid bilayer.

In response, Applicants elect Group I, claims 1-36, without traverse. Claim 37 has been canceled. Applicants reserve the right to pursue the canceled subject matter in a divisional application.

Page 7, lines 1-4 was amended to correct an obvious typographical error in the chemical structure and molecular weight of 3,6-Bis{N-Fumaryl-N-(n-butyl)amino}-2,5-diketopiperazine. No new matter has been added.

Favorable consideration of claims 1-36 is respectfully solicited.

Respectfully submitted,


Rivka D. Monheit
Reg. No. 48,731

Date: June 3, 2005

PABST PATENT GROUP, LLP
400 Colony Square, Suite 1200
1201 Peachtree Street
Atlanta, Georgia 30361
(404) 879-2152
(404) 879-2160 (fax)